Secular trends of HPV genotypes in invasive cervical cancer in Cali, Colombia 1950–1999. (February 2016)

• Record Type: Journal Article
• Authors: Sanchez, Gloria Ines; Bravo, Luis Eduardo; Hernandez-Suarez, Gustavo; Tous, Sara; Alemany, Laia; de Sanjose, Silvia; Bosch, F. Xavier; Muñoz, Nubia
• Is Part Of: Cancer epidemiology. Volume 40(2016:Feb.)
• Page Start: 173
• Page End: 178
• Publication Date: 2016-02
• Subjects: Cervical cancer -- HPV types -- Colombia -- Time trends -- HPV vaccines; Cancer -- Epidemiology -- Periodicals; Cancer -- Prevention -- Periodicals; Cancer -- Diagnosis -- Periodicals; Carcinogenesis -- Periodicals; 616.994005
• DOI: 10.1016/j.canep.2015.12.008
• Languages: English
• ISSNs: 1877-7821

Abstract

Highlights: Relative contribution and time trends of HPV types among HPV+ cervical cancer cases in Cali, Colombia during 50 years were estimated. 64.7% of Squamous cell carcinomas were attributed to HPV 16 and 18, 78.2% to HPV 16, 18, 31, 33 and 45 and 84.48% to HPV 16, 18, 31, 33, 45, 52 and 58. Ninety-three percent of Adenocarcinomas were attributed to HPV 16, 18 and 45 only. The prevalence of specific HPV types was stable over the 50-year period. The age at diagnosis was related to specific HPV type prevalence. Abstract: Aim To estimate relative contribution and time trends of HPV types in cervical cancer in Cali, Colombia over a 50 years' period. Methods: Paraffin blocks of 736 cervical cancer histological confirmed cases were retrieved from the pathology laboratory at Hospital Universitario del Valle (Cali, Colombia) and HPV genotyped using SPF10-PCR/DEIA/LiPA25 (version 1) assay. Marginal effect of age and year of diagnosis in secular trends of HPV type prevalence among HPV+ cases were assessed by robust Poisson regression analysis. Results: 64.7% (95%CI: 59.9–69.2) of squamous cell carcinomas (SCCs) were attributed to HPV 16 and 18, 78.2% (95%CI: 74–82) to HPV 16, 18, 31, 33 and 45 and 84.8% (95%CI: 81–88.1) to HPV 16, 18, 31, 33, 45, 52 and 58 while ninety-three percent of adenocarcinomas (ADCs) were attributed to HPV 16, 18 and 45 only. The prevalence of specific HPV types did not change over the 50-year period. A significant downward trend of prevalence ratios of HPV16 ( ​P = 0.017) and α7 but HPV 18 (i.e., HPV 39, 45, 68, 70, ​P = 0.024) with increasing age at diagnosis was observed. In contrast, the prevalence ratio to other HPV genotypes of α9 but HPV 16 genotypes (i.e., HPV 31, 33, 35, 52, 58, 67, ​P = 0.002) increased with increasing age at diagnosis. Conclusion: No changes were observed in the relative contribution of HPV types in cervical cancer in Cali, Colombia during the 50 years. In this population, an HPV vaccine including the HPV 16, 18, 31, 33, 45, 52 and 58 genotypes may have the potential to prevent ∼85% and 93% of SCC and ADC cases respectively.